<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26066831</article-id><article-id pub-id-type="pmc">4466575</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0129375</article-id><article-id pub-id-type="publisher-id">PONE-D-15-06673</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?</article-title><alt-title alt-title-type="running-head">Trisomy 8 in Myelodysplastic Syndromes</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Saumell</surname><given-names>S&#x000ed;lvia</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sol&#x000e9;</surname><given-names>Francesc</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arenillas</surname><given-names>Leonor</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Montoro</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Valc&#x000e1;rcel</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pedro</surname><given-names>Carme</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sanzo</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lu&#x000f1;o</surname><given-names>Elisa</given-names></name><xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gim&#x000e9;nez</surname><given-names>Teresa</given-names></name><xref ref-type="aff" rid="aff008">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arnan</surname><given-names>Montserrat</given-names></name><xref ref-type="aff" rid="aff009">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pomares</surname><given-names>Helena</given-names></name><xref ref-type="aff" rid="aff009">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>De Paz</surname><given-names>Raquel</given-names></name><xref ref-type="aff" rid="aff010">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arrizabalaga</surname><given-names>Beatriz</given-names></name><xref ref-type="aff" rid="aff011">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jerez</surname><given-names>Andr&#x000e9;s</given-names></name><xref ref-type="aff" rid="aff012">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez</surname><given-names>Ana B.</given-names></name><xref ref-type="aff" rid="aff012">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>S&#x000e1;nchez-Castro</surname><given-names>Judith</given-names></name><xref ref-type="aff" rid="aff013">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rodr&#x000ed;guez-Gambarte</surname><given-names>Juan D.</given-names></name><xref ref-type="aff" rid="aff014">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Raya</surname><given-names>Jos&#x000e9; M.</given-names></name><xref ref-type="aff" rid="aff015">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>R&#x000ed;os</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="aff016">
<sup>16</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rodr&#x000ed;guez-Rivera</surname><given-names>Mar&#x000ed;a</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Espinet</surname><given-names>Blanca</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Florensa</surname><given-names>Lourdes</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Laboratori de Citologia Hematol&#x000f2;gica i Citogen&#x000e8;tica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>GRETNHE, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Department of Medicine, Medicine Faculty, Universitat Aut&#x000f2;noma de Barcelona, Bellaterra, Spain</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>Institut de Recerca Contra la Leuc&#x000e8;mia Josep Carreras, Cytogenetics Platform, Badalona, Spain</addr-line>
</aff><aff id="aff005">
<label>5</label>
<addr-line>Servicio de Hematolog&#x000ed;a, Hospital Vall d&#x02019;Hebr&#x000f3;n, Barcelona, Spain</addr-line>
</aff><aff id="aff006">
<label>6</label>
<addr-line>Servei de Hematologia Cl&#x000ed;nica, Hospital del Mar, Barcelona, Spain</addr-line>
</aff><aff id="aff007">
<label>7</label>
<addr-line>Servicio de Hematolog&#x000ed;a, Hospital Central de Asturias, Oviedo, Spain</addr-line>
</aff><aff id="aff008">
<label>8</label>
<addr-line>Servei d&#x02019;Hematologia, Hospital Universitari Joan XXIII, Tarragona, Spain</addr-line>
</aff><aff id="aff009">
<label>9</label>
<addr-line>Servei d&#x02019;Hematologia, Hospital Duran i Reynals, Institut Catal&#x000e0; d&#x02019;Oncologia, L&#x02019;Hospitalet del Llobregat, Spain</addr-line>
</aff><aff id="aff010">
<label>10</label>
<addr-line>Servicio de Hematolog&#x000ed;a, Hospital Universitario de La Paz, Madrid, Spain</addr-line>
</aff><aff id="aff011">
<label>11</label>
<addr-line>Servicio de Hematologia, Hospital Universitario de Cruces, Baracaldo, Spain</addr-line>
</aff><aff id="aff012">
<label>12</label>
<addr-line>Servicio de Hematolog&#x000ed;a, Hospital Morales Meseguer, Murcia, Spain</addr-line>
</aff><aff id="aff013">
<label>13</label>
<addr-line>Servei d&#x02019; Hematologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain</addr-line>
</aff><aff id="aff014">
<label>14</label>
<addr-line>Servicio de Hematolog&#x000ed;a, Hospital Universitario Ramon y Cajal, Madrid, Spain</addr-line>
</aff><aff id="aff015">
<label>15</label>
<addr-line>Servicio de Hematolog&#x000ed;a, Hospital Universitario de Canarias, La Laguna,Tenerife, Spain</addr-line>
</aff><aff id="aff016">
<label>16</label>
<addr-line>Sevicio de Hematologia, Hospital Universitario de Valme, Sevilla, Spain</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Mills</surname><given-names>Ken</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Queen's University Belfast, UNITED KINGDOM</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: SS FS LF. Performed the experiments: SS MR. Analyzed the data: SS FS LF. Contributed reagents/materials/analysis tools: MR BE. Wrote the paper: SS LF. Reviewed the manuscript: FS DV LA JMR BE. Provided patient samples and clinical data: LA JM DV CP CS EL TG MA HP RDP BA AJ ABM JS JDR JMR ER.</p></fn><corresp id="cor001">* E-mail: <email>lflorensa@parcdesalutmar.cat</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>6</issue><elocation-id>e0129375</elocation-id><history><date date-type="received"><day>20</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>7</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Saumell et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Saumell et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0129375.pdf"/><abstract><p>Isolated trisomy 8 is not considered presumptive evidence of myelodysplastic syndrome (MDS) in cases without minimal morphological criteria. One reason given is that trisomy 8 (+8) can be found as a constitutional mosaicism (cT8M). We tried to clarify the incidence of cT8M in myeloid neoplasms, specifically in MDS, and the diagnostic value of isolated +8 in MDS. Twenty-two MDS and 10 other myeloid neoplasms carrying +8 were studied. Trisomy 8 was determined in peripheral blood by conventional cytogenetics (CC) and on granulocytes, CD3+ lymphocytes and oral mucosa cells by fluorescence <italic>in situ</italic> hybridization (FISH). In peripheral blood CC, +8 was seen in 4/32 patients. By FISH, only one patient with chronic myelomonocytic leukemia showed +8 in all cell samples and was interpreted as a cT8M. In our series +8 was acquired in all MDS. Probably, once discarded cT8M by FISH from CD3+ lymphocytes and non-hematological cells, +8 should be considered with enough evidence to MDS.</p></abstract><funding-group><funding-statement>This work was supported by Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo, Spain (FI07/00107, CA08/00141; PI07/1009 and PI 11/02010); Red Tem&#x000e1;tica de Investigaci&#x000f3;nCooperativa en C&#x000e1;ncer (RTICC, FEDER) (RD06/0020/0031 and RD07/0020/2004; RD12/0036/0044); SGR 541/2009 (&#x0201c;Ag&#x000e8;ncia de Gesti&#x000f3; d&#x02019;Ajuts Universitaris i de Recerca&#x0201d;, Departament d&#x02019;Innovaci&#x000f3;, Universitats i Empresa); Acci&#x000f3;n COST BM0801: European Genetic and Epigentic Study on AML and MDS; Sociedad Espa&#x000f1;ola de Hematolog&#x000ed;a y Hemoterapia (SEHH) 2011 and 2012 fellowships.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="1"/><page-count count="7"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Myelodysplastic syndromes (MDS) are a heterogeneous group of acquired clonal hematopoietic stem cell disorders with increased risk of acute myeloid leukemia (AML) development. Diagnosis of MDS remains among the most challenging of the myeloid neoplasms and is based on the presence of cytopenia(s), dysplasia in one or more myeloid lineages and less than 20% bone marrow (BM) or peripheral blood (PB) blasts [<xref rid="pone.0129375.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0129375.ref002" ref-type="bibr">2</xref>]. Around 50% of MDS cases presented clonal cytogenetic abnormalities [<xref rid="pone.0129375.ref002" ref-type="bibr">2</xref>]. Trisomy 8 (+8) is the most common chromosome gain in MDS and is present in 5&#x02013;7% of them [<xref rid="pone.0129375.ref003" ref-type="bibr">3</xref>]. MDS patients with isolated +8 are included in the MDS intermediate cytogenetic risk group according to the new revised IPSS (IPSS-R) [<xref rid="pone.0129375.ref004" ref-type="bibr">4</xref>]. Nevertheless, in contrast to other recurring chromosomal alterations, the presence of +8 as the sole cytogenetic abnormality is not considered definitive evidence for MDS in the absence of morphological criteria [<xref rid="pone.0129375.ref002" ref-type="bibr">2</xref>]. Since trisomy 8 was found as a constitutional mosaicism (cT8M) in healthy people, it was not considered a tumour marker by some authors [<xref rid="pone.0129375.ref005" ref-type="bibr">5</xref>]. However, the incidence of cT8M referred is very low; Nielsen and Wohlert detected one case of cT8M among approximately 35000 live births [<xref rid="pone.0129375.ref006" ref-type="bibr">6</xref>], and Seghezzi et al. found two cases out of 40140 [<xref rid="pone.0129375.ref007" ref-type="bibr">7</xref>]. In addition, some studies suggested that +8 could be present as a cT8M in myeloid malignancies [<xref rid="pone.0129375.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0129375.ref010" ref-type="bibr">10</xref>]<sup>,</sup> and Maserati et al. reported that +8 is constitutional in 15&#x02013;20% of MDS and acute leukemia [<xref rid="pone.0129375.ref009" ref-type="bibr">9</xref>]. We have analyzed the presence of +8 in granulocytes and CD3+ lymphocytes from PB, as well as in oral mucosa cells from patients diagnosed with MDS carrying +8, in order to clarify the incidence of cT8M in MDS and try to provide a precise diagnostic and prognostic value for isolated +8, especially in cases where there is a degree of doubt.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><p>A total of 32 patients with +8 were studied from different Spanish hospitals belonging to the <italic>Grupo espa&#x000f1;ol de s&#x000ed;ndromes mielodispl&#x000e1;sicos</italic> (GESMD): 22 diagnosed with MDS and 10 of other myeloid neoplasms. The latter group included four patients with myelodysplastic/ myeloproliferative neoplasm [two chronic myelomonocitic leukemia (CMML) and two refractory anemia with ring sideroblasts and thrombocytosis (RARS-T)] and six patients with AML. Five of the MDS and two of the AML patients had additional cytogenetic alterations to +8 on the bone marrow karyotype. One of the AML had a tetrasomy 8. Furthermore, we also studied 20 healthy controls (12 women and 8 men), with ages ranged between 20&#x02013;60 years.</p><sec id="sec003"><title>Blood Samples</title><p>Lymphocytes and granulocytes were isolated from 30mL of PB using standard cell separation protocols. CD3+ cells were isolated from mononuclear cells by immunomagnetic beads (MiltenyiBiotec, Germany). Afterwards, CD3+ cells, as well as granulocytes, were fixed with Carnoy fixative solution (3:1 methanol to acetic acid), and spread on independent slides for fluorescence <italic>in situ</italic> hybridization (FISH) studies. The decision to study CD3+ cells was based on the discarted involvement of them in MDS [<xref rid="pone.0129375.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0129375.ref016" ref-type="bibr">16</xref>], their practical accessibility, and the recommendations of other authors for germline analisis in SNP and sequencing studies [<xref rid="pone.0129375.ref017" ref-type="bibr">17</xref>&#x02013;<xref rid="pone.0129375.ref019" ref-type="bibr">19</xref>].</p></sec><sec id="sec004"><title>Oral Mucosa</title><p>The oral mucosa was scraped with a sterile cotton swab. Four smears were made by scattering mucosa cells of the swabs over slides. The samples were fixed 10 min in Carnoy solution. Once dried, slides were treated with acetic acid solution (3:2 acetic acid to methanol) at 45&#x000b0;C for 40 min, following with a 10 min digestion in 0.005% pepsin solution (Sigma Aldrich, St Louis, MO) at 37&#x000b0;C, and ending with a dehydratation in 70%, 80% and 100% ethanol wash series.</p></sec><sec id="sec005"><title>Karyotype Analysis</title><p>Metaphase staining chromosome analysis using phytohemagglutinin (PHA) stimulated cultures of PB were carried out by G-banding technique. At least 15 metaphases were analyzed for each patient. The analysis and nomenclature of the chromosomes were based on International System for Human Cytogenetic Nomenclature (ISCN) of 2013 [<xref rid="pone.0129375.ref020" ref-type="bibr">20</xref>].</p></sec><sec id="sec006"><title>Fluorescence <italic>in situ</italic> Hybridization (FISH)</title><p>The centromeric 8 spectrum-orange DNA probe (CEP 8, Vysis, Downers Grove, IL) was applied to CD3+ lymphocytes, granulocytes and oral mucosa cells slides. The hybridization was performed overnight at 37&#x000b0;C. After washing, slides were counterstained with diaminophenylindole (DAPI II). The results of the hybridization were evaluated in a fluorescence microscope. If three signals of the same size and intensity were separated by at least one domain, +8 was considered. Following the European Cytogeneticists Association Specific Constitutional Guidelines [<xref rid="pone.0129375.ref021" ref-type="bibr">21</xref>], +8 mosaicism was assessed in 200 nuclei for CD3+ lymphocytes and granulocytes, and a minimum of 30 mucosa cells were analyzed. According to our laboratory, cutoff points for PB samples as well as for oral mucosa cells were 5%.</p><p>The study was carried out in accordance with the biomedical Helsinki Declaration of research guidelines and was approved by the <italic>Comit&#x000e9; &#x000c9;tico de Investigaci&#x000f3;n Cl&#x000ed;nica (CEIC) Parc de Salut Mar</italic>. All participants provided their written informed consent to participate in the study.</p></sec><sec id="sec007"><title>Statistical analysis</title><p>Overall survival (OS) and time to AML transformation of patients with MDS and +8 were calculated. They were defined to be the time from the MDS diagnosis to death or last follow-up and to development of AML, respectively. Kaplan-Meier method was used to evaluate OS and AML transformation. Data analysis was performed using the R software package (version 3.1.1; R Foundation for Statistical Computing, Vienna, Austria).</p></sec></sec><sec sec-type="results" id="sec008"><title>Results</title><p>The patient characteristics are shown in <xref rid="pone.0129375.t001" ref-type="table">Table 1</xref>. Among 22 patients diagnosed with MDS and +8, 17 cases had isolated +8 on BM karyotype at diagnosis, and five had also other additional alterations. Cytogenetic analysis of PB PHA-stimulated cultures revealed +8 in 3 out of 22 patients in 5% to 65% of cells. Using FISH, trisomy 8 was observed in 3% to 74% of granulocytes from all 18 patients studied (4 patients were not studied for extremely neutropenia). Two of them were not considered positive for not reaching our cut off. For CD3+ cells samples, trisomy 8 was seen in 5 out of 22 patients. However, only 4 of them showed trisomy 8 over 5% (6% to 20%). Probably, those cells with +8 detected in CD3+ isolated samples were monocytes due to contamination during cellular isolation (CD3+ cell purity being 76 to 91.1%). None of the oral mucosa cell slides from 20 patients that could be analyzed showed +8, the other two cases could not be analyzed for unsuccessful hybridization.</p><table-wrap id="pone.0129375.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0129375.t001</object-id><label>Table 1</label><caption><title>Patient Characteristics.</title></caption><alternatives><graphic id="pone.0129375.t001g" xlink:href="pone.0129375.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="5" align="center" rowspan="1">FLUORESCENCE IN SITU HYBRIDIZATION</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">CD3+ LYMPHOCYTES</th><th align="left" rowspan="1" colspan="1">GRANULOCYTES</th><th colspan="2" align="center" rowspan="1">MUCOSA</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1">WHO</th><th align="left" rowspan="1" colspan="1">BONE MARROW KARYOTYPE</th><th align="left" rowspan="1" colspan="1">PB KARYOTYPE (PHA)</th><th align="left" rowspan="1" colspan="1">% cells with +8</th><th align="left" rowspan="1" colspan="1">% of purity</th><th align="left" rowspan="1" colspan="1">% cells with +8</th><th align="left" rowspan="1" colspan="1">% cells with +8</th><th align="left" rowspan="1" colspan="1">N&#x000b0; of cells analyzed</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x000a0;</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>MDS</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x000a0;</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x000a0;</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x000a0;</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x000a0;</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x000a0;</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x000a0;</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x000a0;</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">RA</td><td align="left" rowspan="1" colspan="1">46,XX,del(5)(q13q33)[10]/47,sl,+8[3]/48,sld1,+22[4]/47,XX,+8[5]/46,XX[4]</td><td align="left" rowspan="1" colspan="1">46,XX[20]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">RA</td><td align="left" rowspan="1" colspan="1">47,XY,+8[4]/46,XY[12]</td><td align="left" rowspan="1" colspan="1">46,XY[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">RCUD</td><td align="left" rowspan="1" colspan="1">47,XX,+8[11]/46,XX[9]</td><td align="left" rowspan="1" colspan="1">46,XX[20]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">88</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">75</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XX,+8[10]/46,XX[10]</td><td align="left" rowspan="1" colspan="1">47,XX,+8[5]/46,XX[15]</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">91.1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XY,del(5)(q15q33),+8[20]</td><td align="left" rowspan="1" colspan="1">46,XY[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XY,+8[10]/46,XY[10]</td><td align="left" rowspan="1" colspan="1">46,XY[15]</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XY,+8[7]/46,XY[13]</td><td align="left" rowspan="1" colspan="1">46,XY[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XY,+8[15]/46,XY[5]</td><td align="left" rowspan="1" colspan="1">48,XY,+8,+21[1]/46,XY[19]</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XY,+8[16]/46,XY[4]</td><td align="left" rowspan="1" colspan="1">46,XY[20]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">73</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XX,+8[20]/48,sl,+8[1]/46,XX[7]</td><td align="left" rowspan="1" colspan="1">46,XX[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XX,+8[5]/46,XX[15]</td><td align="left" rowspan="1" colspan="1">46,XX[20]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">89</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XY,+8[8]/46,XY[12]</td><td align="left" rowspan="1" colspan="1">46,XY[20]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XX,+8[5]/46,XX[26]</td><td align="left" rowspan="1" colspan="1">46,XX[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XY,+8[13]/46,XY[7]</td><td align="left" rowspan="1" colspan="1">46,XY[20]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">70</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XX,+8[20]</td><td align="left" rowspan="1" colspan="1">46,XX[20]</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">46,XX,del(5)(q14)[15]/47,XX,+8[2]</td><td align="left" rowspan="1" colspan="1">46,XX[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">RCMD</td><td align="left" rowspan="1" colspan="1">47,XY,+8[8]/46,XY[15]</td><td align="left" rowspan="1" colspan="1">46,XY[20]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">93</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">RAEB-1</td><td align="left" rowspan="1" colspan="1">47,XX,+8[9]/47,sl,i(17)(q10)[9]</td><td align="left" rowspan="1" colspan="1">No metaphases</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">76</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">RAEB-2</td><td align="left" rowspan="1" colspan="1">47,XY,+8[7]/46,XY[13]</td><td align="left" rowspan="1" colspan="1">46,XY[20]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">93</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">53</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">RAEB-2</td><td align="left" rowspan="1" colspan="1">47,XX,+8[2]/46,XX[18]</td><td align="left" rowspan="1" colspan="1">46,XX[20]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">89</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">72</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">RAEB-2</td><td align="left" rowspan="1" colspan="1">45,X,-Y[8]/46,X,-Y,+8[5]</td><td align="left" rowspan="1" colspan="1">46,X,-Y,+8[13]/46,XY[7]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">96.7</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">54</td></tr><tr><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">MDS-U</td><td align="left" rowspan="1" colspan="1">47,XY,+8[19]/46,XY[1]</td><td align="left" rowspan="1" colspan="1">46,XY[20]</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">65</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">
<bold>MDS/MPN</bold>
</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">RARS-T</td><td align="left" rowspan="1" colspan="1">47,XX,+8[4]/46,XX[23]</td><td align="left" rowspan="1" colspan="1">46,XX[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">93</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">31</td></tr><tr><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">RARS-T</td><td align="left" rowspan="1" colspan="1">47,XY,+8[3]/46,XY[17]</td><td align="left" rowspan="1" colspan="1">46,XY[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">36</td></tr><tr><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">CMML</td><td align="left" rowspan="1" colspan="1">47,XY,+8[20]</td><td align="left" rowspan="1" colspan="1">46,XY[15]</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">84.7</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">CMML</td><td align="left" rowspan="1" colspan="1">
<bold>47,XY,+8[15]/46,XY[5]</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>47,XY,+8[2]/46,XY[48]</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>28</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>93</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>60</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>100</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">
<bold>AML</bold>
</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">AML-MDRC</td><td align="left" rowspan="1" colspan="1">47,XY,+8[2]/46,XY[2]</td><td align="left" rowspan="1" colspan="1">46,XY[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">AML NOS</td><td align="left" rowspan="1" colspan="1">No metaphases (FISH+8, 70%)</td><td align="left" rowspan="1" colspan="1">46,XX[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">89</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">AML-MDRC</td><td align="left" rowspan="1" colspan="1">47,XY,+8[20]</td><td align="left" rowspan="1" colspan="1">46,XY[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">83</td></tr><tr><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">APL</td><td align="left" rowspan="1" colspan="1">47,XX,+8,t(15;17)(q22;q12)[15] /46,XX [5]</td><td align="left" rowspan="1" colspan="1">46,XX[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">93</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">AML NOS</td><td align="left" rowspan="1" colspan="1">48,XY,+8,+8[18]</td><td align="left" rowspan="1" colspan="1">46,XY[15]</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">93.8</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">AML-MDRC</td><td align="left" rowspan="1" colspan="1">46,XY,-5,del(7)(q11q35),+8,der(17)t(5;17)(p11;p11)[20]</td><td align="left" rowspan="1" colspan="1">No metaphases</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">84.8</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">100</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>
<bold>Abbreviations:</bold> +8, trisomy 8; PB, peripheral blood; PHA, phytohemagglutinin; RA, refractory anemia; RCUD, refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, RA with excess of blasts; MDS-U, myelodysplastic syndrome unclassified; RARS-T, RA with ringed sideroblasts and thrombocytosis; CMML, chronic myelomonocytic leukemia; AML, acute myeloid leukemia; AML-MDRC, AML with myelodysplasia-related changes; AML NOS, AML not otherwise specified; APL, acute promyelocytic leukemia. In bold patient with constitutional trisomy 8 mosaicism.</p></fn></table-wrap-foot></table-wrap><p>Among the ten patients with other myeloid neoplasms carrying +8, neither patients with RARS-T nor AML ones presented +8 on CD3+ lymphocytes and oral mucosa cells, while one of CMML patients showed trisomy 8 on both of them (CD3+ lymphocytes and oral mucosa cells).</p><p>For the healthy controls, the median of CD3+ cells with trisomy 8 was 1.3% and no cell from mucosa samples showed trisomy 8.</p><sec id="sec009"><title>Outcome analysis</title><p>The data of twenty-one patients with MDS and +8 were available for Kaplan-Meier analysis. Twelve patients died and five evolved to AML with a median follow up of 38.2 months (range, 2.6 to 92.3 months). The median OS and median time to AML transformation for MDS with isolated +8 were 85.9 and 2.8 months, respectively. No statistically significant differences in median OS were found between MDS with isolated +8 and MDS with +8 and another additional aberration.</p></sec></sec><sec sec-type="conclusions" id="sec010"><title>Discussion</title><p>MDS are associated with clonal cytogenetic abnormalities in around 50% of patients [<xref rid="pone.0129375.ref002" ref-type="bibr">2</xref>] being trisomy 8 the most common chromosome gain. According to the IPSS-R, isolated trisomy 8 is included in the intermediate cytogenetic risk group [<xref rid="pone.0129375.ref004" ref-type="bibr">4</xref>]. The current analysis with 22 patients diagnosed of MDS with isolated +8 and selected to be alive at the inclusion moment showed a longer overall survival (median, 85.9 months) than expected. However, in our previous study of 72 MDS with isolated +8 patients from GESMDregistry, the median overall survival was 34.3 months [<xref rid="pone.0129375.ref003" ref-type="bibr">3</xref>], demonstrating the intermediate risk confered by trisomy 8 to MDS and in agreement with IPSS-R. In contrast to other recurring chromosomal alterations, isolated +8 is not considered presumptive evidence of MDS when minimal morphological criteria are lacking [<xref rid="pone.0129375.ref002" ref-type="bibr">2</xref>]. This is in part because +8 may be derived from a constitutional 8 mosaicism. Furthermore, the incidence of cT8M among general population is very low [<xref rid="pone.0129375.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0129375.ref007" ref-type="bibr">7</xref>]. In accordance, none of our healthy controls showed trisomy 8 by FISH. In 2002, Maserati <italic>et al</italic>. reported that +8 in myelodysplasia and acute leukemia is constitutional in 15&#x02013;20% [<xref rid="pone.0129375.ref009" ref-type="bibr">9</xref>]. They had analyzed 13 cases of different myeloid neoplasms (including seven MDS) and 1 case of acute lymphoblastic leukemia and reported a cT8M in two of them after applying conventional cytogenetics from PB PHA-stimulated cultures. Nevertheless, in that study the cT8M was confirmed on a skin fibroblasts culture in only one MDS patient. Some other previous studies to determine lineage involvement in MDS, demonstrated that +8 was only found in myeloid lineage (granulocytes, monocytes and erythroblasts) [<xref rid="pone.0129375.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0129375.ref016" ref-type="bibr">16</xref>]. These studies did not analyze non-hematopoietic cells because of their different aim. We evaluated the presence of +8 in 32 patients with different myeloid neoplasms (22 MDS, 2 RARS-T, 2 CMML and 6 AML). In all but one patient, we observed the +8 in myeloid cells and ruled it out in CD3+ lymphocytes and mucosa cells by FISH. Regarding the remaining patient, with +8 in both lymphocytes and mucosa cells, we could consider this alteration as constitutional. We believe that G-banding cytogenetics from PB PHA-stimulated cultures is not useful to discard cT8M, because myeloid cells present in these samples may also divide, giving a false positive result. In fact in our series, karyotype of PB showed +8 in 3 MDS patients but none of them presented +8 in oral mucosa samples. Hence, we consider it mandatory to apply FISH on isolated CD3+ lymphocytes as well as on non-hematological cells as oral mucosa ones for mosaicism studies. In the present project, the study of mucosa cells helps to rule out the germinal nature of trisomy 8 in those cases with residual positive CD3+ cells from samples with low purity. Non-use of the FISH technique on non-hematological cells probably explains the higher cT8M incidence reported from Maserati analyses in a short series with only 7 MDS patients [<xref rid="pone.0129375.ref009" ref-type="bibr">9</xref>]. Moreover, it is interesting to point out that the CMML patient with constitutional +8 had been diagnosed with a Beh&#x000e7;et syndrome. Curiously the association between the presence of a cT8M and increased risk of developing Beh&#x000e7;et syndrome [<xref rid="pone.0129375.ref022" ref-type="bibr">22</xref>] as well as a high risk of developing myeloid neoplasms [<xref rid="pone.0129375.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0129375.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0129375.ref023" ref-type="bibr">23</xref>], have already been referred.</p><p>Another argument used against the value of +8 to diagnose MDS is the possible presence of +8 as a seemingly clonal aberration in aplastic anemia (AA), which may disappear after immunosuppressive treatment [<xref rid="pone.0129375.ref024" ref-type="bibr">24</xref>]. Also Maciejewsky et al. have described a clonal evolution to MDS as a late complication of AA [<xref rid="pone.0129375.ref025" ref-type="bibr">25</xref>]. Thus, +8 in the absence of unequivocal dysplasia, would not be of help to differentiate hypocellular MDS from AA, entities that have been suggested to share similar pathogenic process for bone marrow hypocellularity [<xref rid="pone.0129375.ref026" ref-type="bibr">26</xref>]. Furthermore, a significant response rate of MDS with +8 to immunosuppressive therapy is well known [<xref rid="pone.0129375.ref027" ref-type="bibr">27</xref>].</p><p>In summary, our study confirms that cT8M should be ruled out using FISH on CD3+ lymphocytes and on non-hematological cells such as oral mucosa ones in MDS, and to the best of our knowledge, is the first study performed under these conditions. Besides this, our results suggest that trisomy 8 is acquired in almost all MDS, and probably, isolated +8 should be considered with enough evidence to diagnose MDS in normo and hypercellular bone marrow cases. Studies with longer series are needed for more decisive conclusions.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0129375.ref001"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Tefferi</surname><given-names>A</given-names></name>, <name><surname>Vardiman</surname><given-names>JW</given-names></name>. <article-title>Myelodysplastic syndromes</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>:<fpage>1872</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">19890130</pub-id></mixed-citation></ref><ref id="pone.0129375.ref002"><label>2</label><mixed-citation publication-type="book">
<name><surname>Brunning</surname><given-names>R</given-names></name>, <name><surname>Orazi</surname><given-names>A</given-names></name>, <name><surname>Germing</surname><given-names>U</given-names></name>, <name><surname>Le Beau</surname><given-names>MM</given-names></name>, <name><surname>Porwit</surname><given-names>A</given-names></name>, <name><surname>Baumann</surname><given-names>I</given-names></name>, <etal>et al</etal>
<chapter-title>Myelodysplastic syndromes/neoplasms overview</chapter-title> In: <name><surname>Swerdlow</surname><given-names>SH</given-names></name>, <name><surname>Campo</surname><given-names>E</given-names></name>, <name><surname>Harris</surname><given-names>NL</given-names></name>, <name><surname>Jaffe</surname><given-names>ES</given-names></name>, <name><surname>Pileri</surname><given-names>SA</given-names></name>, <name><surname>Stein</surname><given-names>H</given-names></name>, et al. editors. <source>WHO classification of tumours of haematopoietic and lymphoid tissues</source>. <italic>World Health Organization</italic>
<publisher-loc>Lyon</publisher-loc>: <publisher-name>IARC</publisher-name>, <year>2008</year>, p. <fpage>88</fpage>&#x02013;<lpage>93</lpage>.</mixed-citation></ref><ref id="pone.0129375.ref003"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Saumell</surname><given-names>S</given-names></name>, <name><surname>Florensa</surname><given-names>L</given-names></name>, <name><surname>Lu&#x000f1;o</surname><given-names>E</given-names></name>, <name><surname>Sanzo</surname><given-names>C</given-names></name>, <name><surname>Ca&#x000f1;izo</surname><given-names>C</given-names></name>, <name><surname>Hern&#x000e1;ndez</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes</article-title>. <source>B J Haemat</source>. <year>2012</year>;<volume>159</volume>:<fpage>311</fpage>&#x02013;<lpage>21</lpage>.</mixed-citation></ref><ref id="pone.0129375.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Greenberg</surname><given-names>PL</given-names></name>, <name><surname>Tuechler</surname><given-names>H</given-names></name>, <name><surname>Schanz</surname><given-names>J</given-names></name>, <name><surname>Sanz</surname><given-names>G</given-names></name>, <name><surname>Garcia-Manero</surname><given-names>G</given-names></name>, <name><surname>Sol&#x000e9;</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes</article-title>. <source>Blood</source>. <year>2012</year>;<volume>120</volume>:<fpage>2454</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">22740453</pub-id></mixed-citation></ref><ref id="pone.0129375.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Hasle</surname><given-names>H</given-names></name>, <name><surname>Clausen</surname><given-names>N</given-names></name>, <name><surname>Pedersen</surname><given-names>B</given-names></name>, <name><surname>Bendix-Hansen</surname><given-names>K</given-names></name>. <article-title>Myelodysplastic syndrome in a child with constitutional trisomy 8 mosaicism and normal phenotype</article-title>. <source>Cancer Genet and Cytogenet</source>.<year>1995</year>;<volume>79</volume>:<fpage>79</fpage>&#x02013;<lpage>81</lpage>.
<pub-id pub-id-type="pmid">7850757</pub-id></mixed-citation></ref><ref id="pone.0129375.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Nielsen</surname><given-names>J</given-names></name>, <name><surname>Wohlert</surname><given-names>M</given-names></name>. <article-title>Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in arhus, denmark</article-title>. <source>Hum Genet</source>.<year>1991</year>;<volume>87</volume>:<fpage>81</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">2037286</pub-id></mixed-citation></ref><ref id="pone.0129375.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Seghezzi</surname><given-names>L</given-names></name>, <name><surname>Maserati</surname><given-names>E</given-names></name>, <name><surname>Minelli</surname><given-names>A</given-names></name>, <name><surname>Dellavecchia</surname><given-names>C</given-names></name>, <name><surname>Addis</surname><given-names>P</given-names></name>, <name><surname>Locatelli</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Constitutional trisomy 8 as first mutation in multistep carcinogenesis: clinical, cytogenetic, and molecular data on three cases</article-title>. <source>Genes Chromosom Cancer</source>. <year>1996</year>;<volume>17</volume>:<fpage>94</fpage>&#x02013;<lpage>101</lpage>.
<pub-id pub-id-type="pmid">8913726</pub-id></mixed-citation></ref><ref id="pone.0129375.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Ganmore</surname><given-names>I</given-names></name>, <name><surname>Smooha</surname><given-names>G</given-names></name>, <name><surname>Izraeli</surname><given-names>S</given-names></name>. <article-title>Constitutional aneuploidy and cancer predisposition</article-title>. <source>Hum Mol Genet</source>. <year>2009</year>;<volume>18</volume>(<issue>R1</issue>):<fpage>R84</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddp084</pub-id>
<pub-id pub-id-type="pmid">19297405</pub-id></mixed-citation></ref><ref id="pone.0129375.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Maserati</surname><given-names>E</given-names></name>, <name><surname>Aprili</surname><given-names>F</given-names></name>, <name><surname>Vinante</surname><given-names>F</given-names></name>, <name><surname>Locatelli</surname><given-names>F</given-names></name>, <name><surname>Amendola</surname><given-names>G</given-names></name>, <name><surname>Zatterale</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15&#x02013;20% of cases</article-title>. <source>Genes Chromosom Cancer</source>. <year>2002</year>;<volume>33</volume>:<fpage>93</fpage>&#x02013;<lpage>7</lpage>.
<pub-id pub-id-type="pmid">11746991</pub-id></mixed-citation></ref><ref id="pone.0129375.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Ripperger</surname><given-names>T</given-names></name>, <name><surname>Tauscher</surname><given-names>M</given-names></name>, <name><surname>Praulich</surname><given-names>I</given-names></name>, <name><surname>Pabst</surname><given-names>B</given-names></name>, <name><surname>Teigler-Schlegel</surname><given-names>A</given-names></name>, <name><surname>Yeoh</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Constitutional trisomy 8p11.21- q11.21 mosaicism: a germline alteration predisposing to myeloid leukaemia</article-title>. <source>B J Haemat</source>. <year>2011</year>;<volume>155</volume>:<fpage>209</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="pone.0129375.ref011"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Kibbelaar</surname><given-names>RE</given-names></name>, <name><surname>van Kamp</surname><given-names>H</given-names></name>, <name><surname>Dreef</surname><given-names>EJ</given-names></name>, <name><surname>de Groot-Swings</surname><given-names>G</given-names></name>, <name><surname>Kluin-Nelemans</surname><given-names>JC</given-names></name>, <name><surname>Beverstock</surname><given-names>GC</given-names></name>, <etal>et al</etal>
<article-title>Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes</article-title>. <source>Blood</source>. <year>1992</year>;<volume>79</volume>:<fpage>1823</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">1558974</pub-id></mixed-citation></ref><ref id="pone.0129375.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Anastasi</surname><given-names>J</given-names></name>, <name><surname>Feng</surname><given-names>J</given-names></name>, <name><surname>Le Beau</surname><given-names>MM</given-names></name>, <name><surname>Larson</surname><given-names>RA</given-names></name>, <name><surname>Rowley</surname><given-names>JD</given-names></name>, <name><surname>Vardiman</surname><given-names>JW</given-names></name>. <article-title>Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion</article-title>. <source>Blood</source>.<year>1993</year>;<volume>81</volume>:<fpage>1580</fpage>&#x02013;<lpage>5</lpage>.
<pub-id pub-id-type="pmid">8453104</pub-id></mixed-citation></ref><ref id="pone.0129375.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Soenen</surname><given-names>V</given-names></name>, <name><surname>Fenaux</surname><given-names>P</given-names></name>, <name><surname>Flactif</surname><given-names>M</given-names></name>, <name><surname>Lepelley</surname><given-names>P</given-names></name>, <name><surname>Lai</surname><given-names>JL</given-names></name>, <name><surname>Cosson</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Combined immunophenotyping and in situ hybridization (FICTION): a rapid method to study cell lineage involvement in myelodysplastic syndromes</article-title>. <source>B J Haemat</source>.<year>1995</year>;<volume>90</volume>:<fpage>701</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0129375.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Fagioli</surname><given-names>F</given-names></name>, <name><surname>Cuneo</surname><given-names>A</given-names></name>, <name><surname>Bardi</surname><given-names>A</given-names></name>, <name><surname>Carli</surname><given-names>MG</given-names></name>, <name><surname>Bigoni</surname><given-names>R</given-names></name>, <name><surname>Balsamo</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Heterogeneity of lineage involvement by trisomy 8 in myelodysplastic syndrome. a multiparameter analysis combining conventional cytogenetics, dna in situ hybridization, and bone marrow culture studies</article-title>. <source>Cancer Genet Cytogenet</source>. <year>1995</year>;<volume>82</volume>:<fpage>116</fpage>&#x02013;<lpage>22</lpage>.
<pub-id pub-id-type="pmid">7664240</pub-id></mixed-citation></ref><ref id="pone.0129375.ref015"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Bernell</surname><given-names>P</given-names></name>, <name><surname>Jacobsson</surname><given-names>B</given-names></name>, <name><surname>Nordgren</surname><given-names>A</given-names></name>, <name><surname>Hast</surname><given-names>J</given-names></name>. <article-title>Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology</article-title>. <source>Leukemia</source>. <year>1996</year>;<volume>10</volume>:<fpage>662</fpage>&#x02013;<lpage>8</lpage>.
<pub-id pub-id-type="pmid">8618444</pub-id></mixed-citation></ref><ref id="pone.0129375.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Saitoh</surname><given-names>K</given-names></name>, <name><surname>Miura</surname><given-names>I</given-names></name>, <name><surname>Takahashi</surname><given-names>N</given-names></name>, <name><surname>Miura</surname><given-names>AB</given-names></name>. <article-title>Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes</article-title>. <source>Blood</source>. <year>1998</year>;<volume>92</volume>:<fpage>2886</fpage>&#x02013;<lpage>92</lpage>.
<pub-id pub-id-type="pmid">9763574</pub-id></mixed-citation></ref><ref id="pone.0129375.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Tiu</surname><given-names>RV</given-names></name>, <name><surname>Gondek</surname><given-names>LP</given-names></name>, <name><surname>O'Keefe</surname><given-names>CL</given-names></name>, <name><surname>Elson</surname><given-names>P</given-names></name>, <name><surname>Huh</surname><given-names>J</given-names></name>, <name><surname>Mohamedali</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies</article-title>. <source>Blood</source>. <year>2011</year>;<volume>117</volume>:<fpage>4552</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2010-07-295857</pub-id>
<pub-id pub-id-type="pmid">21285439</pub-id></mixed-citation></ref><ref id="pone.0129375.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Yoshida</surname><given-names>K</given-names></name>, <name><surname>Sanada</surname><given-names>M</given-names></name>, <name><surname>Shiraishi</surname><given-names>Y</given-names></name>, <name><surname>Nowak</surname><given-names>D</given-names></name>, <name><surname>Nagata</surname><given-names>Y</given-names></name>, <name><surname>Sato-Otsubo</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Frequent pathway mutations of splicing machinery in myelodysplasia</article-title>. <source>Nature</source>. <year>2011</year>;<volume>478</volume>:<fpage>64</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature10496</pub-id>
<pub-id pub-id-type="pmid">21909114</pub-id></mixed-citation></ref><ref id="pone.0129375.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Mallo</surname><given-names>M</given-names></name>, <name><surname>Del Rey</surname><given-names>M</given-names></name>, <name><surname>Iba&#x000f1;ez</surname><given-names>M</given-names></name>, <name><surname>Calasanz</surname><given-names>MJ</given-names></name>, <name><surname>Arenillas</surname><given-names>L</given-names></name>, <name><surname>Larrayoz</surname><given-names>MJ</given-names></name>, <etal>et al</etal>
<article-title>Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations</article-title>. <source>B J Haemat</source>. <year>2013</year>;<volume>162</volume>:<fpage>74</fpage>&#x02013;<lpage>86</lpage>.</mixed-citation></ref><ref id="pone.0129375.ref020"><label>20</label><mixed-citation publication-type="book">
<name><surname>Shaffer</surname><given-names>L</given-names></name>, <name><surname>McGowan-Jordan</surname><given-names>J</given-names></name>, <name><surname>Schmid</surname><given-names>M</given-names></name>. <chapter-title>An international system for human cytogenetic nomenclature (2013)</chapter-title>
<publisher-loc>Basel</publisher-loc>: <publisher-name>S Karger</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="pone.0129375.ref021"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Hastings</surname><given-names>R</given-names></name>, <name><surname>Howell</surname><given-names>R</given-names></name>, <name><surname>Bricarelli</surname><given-names>FD</given-names></name>, <name><surname>Kristoffersson</surname><given-names>U</given-names></name>, <name><surname>Cavani</surname><given-names>S</given-names></name>. <article-title>Specific constitutional cytogenetic guidelines. <italic>European cytogeneticists associationnewsletter no. 30</italic>
</article-title>. <source>European Cytogeneticists Guidelines. E.C.A.</source>
<year>2012</year>;<volume>30</volume>:<fpage>11</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0129375.ref022"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Becker</surname><given-names>K</given-names></name>, <name><surname>Fitzgerald</surname><given-names>O</given-names></name>, <name><surname>Green</surname><given-names>AJ</given-names></name>, <name><surname>Keogan</surname><given-names>M</given-names></name>, <name><surname>Newbury-Ecob</surname><given-names>R</given-names></name>, <name><surname>Greenhalgh</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Constitutional trisomy 8 and Beh&#x000e7;et syndrome</article-title>. <source>Am J Med Genet</source>. <year>2009</year>;<volume>149A</volume>:<fpage>982</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.32756</pub-id>
<pub-id pub-id-type="pmid">19353586</pub-id></mixed-citation></ref><ref id="pone.0129375.ref023"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Danesino</surname><given-names>C</given-names></name>, <name><surname>Pasquali</surname><given-names>F</given-names></name>, <name><surname>Dellavecchia</surname><given-names>C</given-names></name>, <name><surname>Maserati</surname><given-names>E</given-names></name>, <name><surname>Mineli</surname><given-names>A</given-names></name>, <name><surname>Seghezzi</surname><given-names>L</given-names></name>. <article-title>Constitutional trisomy 8 mosaicism: mechanism of origin, phenotype variability, and risk of malignancies</article-title>. <source>Am J Med Genet</source>. <year>1998</year>;<volume>80</volume>:<fpage>540</fpage>
<pub-id pub-id-type="pmid">9880228</pub-id></mixed-citation></ref><ref id="pone.0129375.ref024"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Vardiman</surname><given-names>JW</given-names></name>, <name><surname>Thiele</surname><given-names>J</given-names></name>, <name><surname>Arber</surname><given-names>DA</given-names></name>, <name><surname>Brunning</surname><given-names>RD</given-names></name>, <name><surname>Borowitz</surname><given-names>MJ</given-names></name>, <name><surname>Porwit</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes</article-title>. <source>Blood</source>. <year>2009</year>;<volume>114</volume>:<fpage>937</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2009-03-209262</pub-id>
<pub-id pub-id-type="pmid">19357394</pub-id></mixed-citation></ref><ref id="pone.0129375.ref025"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Maciejewski</surname><given-names>JP</given-names></name>, <name><surname>Risitano</surname><given-names>A</given-names></name>, <name><surname>Sloand</surname><given-names>EM</given-names></name>, <name><surname>Nunez</surname><given-names>O</given-names></name>, <name><surname>Young</surname><given-names>NO</given-names></name>. <article-title>Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia</article-title>. <source>Blood</source>. <year>2002</year>;<volume>99</volume>:<fpage>3129</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">11964274</pub-id></mixed-citation></ref><ref id="pone.0129375.ref026"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Barrett</surname><given-names>J</given-names></name>, <name><surname>Saunthararajah</surname><given-names>Y</given-names></name>, <name><surname>Molldrem</surname><given-names>J</given-names></name>. <article-title>Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?</article-title>.<source>Semin Hematol</source>. <year>2000</year>;<volume>37</volume>:<fpage>15</fpage>&#x02013;<lpage>29</lpage>.</mixed-citation></ref><ref id="pone.0129375.ref027"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Sloand</surname><given-names>EM</given-names></name>, <name><surname>Mainwaring</surname><given-names>L</given-names></name>, <name><surname>Fuhrer</surname><given-names>M</given-names></name>, <name><surname>Ramkissoon</surname><given-names>S</given-names></name>, <name><surname>Risitano</surname><given-names>AM</given-names></name>, <name><surname>Keyvanafar</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome</article-title>. <source>Blood</source>. <year>2005</year>;<volume>106</volume>:<fpage>841</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">15827127</pub-id></mixed-citation></ref></ref-list></back></article>